National study , a randomized, controlled , open-label , parallel-group study to compare the efficacy and safety of two different approaches with titration algorithm ( run by the medical vs managed by the patient ) for a new therapy with insulin glargine U300 in patients with diabetes type 2.
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 15 Feb 2018 Status changed from recruiting to completed.
- 01 Sep 2015 New trial record